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Association between antipsychotic/antidepressant drug
treatments and hospital admissions in schizophrenia
assessed using a mental health case register
Rudolf N Cardinal1,2, George Savulich1, Louisa M Mann2 and Emilio Fernández-Egea1,2
BACKGROUND: The impact of psychotropic drug choice upon admissions for schizophrenia is not well understood.
AIMS: To examine the association between antipsychotic/antidepressant use and time in hospital for patients with schizophrenia.
METHODS: We conducted an observational study, using 8 years’ admission records and electronically generated drug histories
from an institution providing secondary mental health care in Cambridgeshire, UK, covering the period 2005–2012 inclusive.
Patients with a coded ICD-10 diagnosis of schizophrenia were selected. The primary outcome measure was the time spent as an
inpatient in a psychiatric unit. Antipsychotic and antidepressant drugs used by at least 5% of patients overall were examined for
associations with admissions. Periods before and after drug commencement were compared for patients having pre-drug
admissions, in mirror-image analyses correcting for overall admission rates. Drug use in one 6-month calendar period was used to
predict admissions in the next period, across all patients, in a regression analysis accounting for the effects of all other drugs
studied and for time.
RESULTS: In mirror-image analyses, sulpiride, aripiprazole, clozapine, and olanzapine were associated with fewer subsequent
admission days. In regression analyses, sulpiride, mirtazapine, venlafaxine, and clozapine–aripiprazole and clozapine–amisulpride
combinations were associated with fewer subsequent admission days.
CONCLUSIONS: Use of these drugs was associated with fewer days in hospital. Causation is not implied and these ﬁndings require
conﬁrmation by randomized controlled trials.
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INTRODUCTION
Admissions to psychiatric inpatient units are a potential marker
of disease severity in schizophrenia, and a burden on the indivi-
dual. UK guidelines emphasize avoiding admission, and anti-
psychotic drugs as the mainstay of treatment.1 Randomized2,3 and
non-randomized4–8 studies have examined the effect of some
antipsychotics on admissions. However, information on admission
reduction is sparser across the full range of drugs used clinically,
and in relation to multiple-drug strategies such as clozapine
augmentation9,10 and antidepressant addition.11
We sought to examine the impact of individual antipsychotic
drugs but also of commonly prescribed antidepressants and
clozapine augmentation strategies on hospital admissions in
patients with schizophrenia, using a naturalistic clinical sample
across an 8-year period.
We examined the anonymized electronic records of patients
with schizophrenia within an NHS Trust. We investigated the
associations between the antipsychotics/antidepressants used and
time spent in hospital. To examine the impact of drug initiation
on patients with relatively severe schizophrenia, we conducted
mirror-image analyses examining the duration of admissions
before and after drug initiation, in all patients who had been
admitted during the pre-drug period, controlling for overall
changes in admission rate. To account for the use of more than
one drug and to address additional confounds, we also conducted
regression analyses to model admission durations by drug
prescription, across all patients and drugs.
MATERIALS AND METHODS
Data sources
Cambridgeshire and Peterborough NHS Foundation Trust (CPFT) provides
secondary mental health care to Cambridgeshire (population ~ 800,000).12
Its electronic records from 2005 to 2012 were de-identiﬁed using CRIS13
into a research database (UK NHS National Research Ethics Service
reference 12/EE/0407). Unstructured text, such as letters and discharge
summaries, were searched using GATE14 natural language processing (NLP)
software for drug names and common misspellings in a grammatical
context indicating current use, generating drug histories.15 The principal
data sources were electronic psychiatric admission logs, autogenerated
drug histories, and coded ICD-10 diagnoses.16 Diagnoses were assigned by
clinicians (though sometimes subsequently recorded in structured ﬁelds by
administrative staff) and clinicians were the predominant authors of free-
text documents referencing medication use. Admission and discharge
information was typically recorded by administrative staff. No electronic
prescribing system was in use, necessitating the use of computer-
generated drug histories.
Inclusion and exclusion criteria and measures of illness duration
We studied patients for whom an ICD-10 diagnosis within ‘F20’
(schizophrenia) had been recorded in a structured ‘diagnosis’ ﬁeld at
some point. The ﬁrst such entry was taken as the date of diagnosis of
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schizophrenia. In some cases, electronic diagnoses had been entered with
retrospective dates. For patients who had died, time after death was
excluded.
Dependent variables
The primary dependent variable was the number of days spent as an
inpatient (discharge date minus admission date, summed across
admissions).
Drugs analyzed
We searched for ﬁrst-generation and second-generation antipsychotics
(FGAs, SGAs), plus all UK-licensed antidepressants. We restricted further
analyses to drugs used by ⩾ 5% of patients. In regression analyses, to
reduce confounding from co-prescription, we also included benzodiaze-
pines/Z-drugs and mood stabilizers used by ⩾ 5% of patients. We
calculated a median dose (as the median of all patients’ median daily
doses).
Precision and recall
Precision and recall were measured for clozapine (see Supplementary
Methods).
Mirror-image comparisons of admission rates during pre-drug and
post-drug periods
We calculated a pre- versus post-drug comparison using a mirror-image
design17 (Figure 1), for all drugs studied. For each patient, we calculated a
start date (the study start date or their ﬁrst diagnosis of schizophrenia,
whichever was later), an end date (the study end date or their date of
death if they had died, whichever was earlier), and the ‘ﬁrst use’ date for
each drug. Because of potential temporal imprecision in the exact ﬁrst-use
date, and to reduce the impact of regression to the mean, we excluded a
central period C either side of the ﬁrst-use date (giving a central gap of 2C),
and then looked at a mirrored period M either side of that central gap
(Figure 1). We examined a temporally narrow period (M=1 year) and a
temporally broader period (M=2 years).
We excluded any patient if their mirror period was not within the start–
end date range (i.e., if they had taken the drug soon after diagnosis, lacking
sufﬁcient pre-drug time, or if their ﬁrst-use date was close to their end
date, lacking sufﬁcient post-drug time). Thus, as far as could be established
electronically, all patients in this analysis had a period free of the drug of
interest, commencement of the drug in question, and a period of equal
duration subsequently. We calculated the number of admission days in the
M1 and M2 periods.
As our interest was in the potential impact of treatments upon
admissions, and the inclusion of large numbers of relatively well patients
(having few admissions) would reduce power, we excluded all patients
with zero admission days in M1 before comparing pre- and post-drug
periods. Therefore, in this analysis we studied relatively unwell patients.
Overall admission rates decreased over time. If this effect were not itself
due to treatments, then it would bias results in favor of treatments. We
therefore corrected for overall admission rates. For each mirror period (M1
and M2), in addition to the per-subject admission rates x1 and x2, we
calculated the mean admission rate for all patients, μ1 and μ2. Then,
instead of analyzing (x2–x1), we analyzed and report [(x2–μ2)–(x1–μ1)].
Regression analysis
All patients were analyzed simultaneously via a mixed-effects general
linear model. We divided time into 6-month periods. The dependent
variable was the number of inpatient days per patient per period
(re-expressed as admission days per year). The predictors were: subject
(a random factor), calendar period (to control for overall changes in
admission rates; linear ﬁxed effect), sex (factorial ﬁxed effect), time since
diagnosis (from the ﬁrst recorded diagnosis of schizophrenia to the mid-
point of the period in question, as an estimate of illness duration; linear
ﬁxed effect), age (though this correlates with time since diagnosis; linear
ﬁxed effect), and whether the patient was or was not documented as
taking each drug in the immediately preceding period (factorial ﬁxed
effects; data from the very ﬁrst period were therefore not modeled; total
subject n= 1,406). Subjects contributed only whole periods (not contribut-
ing to a period if it began before their ﬁrst diagnosis of schizophrenia, or
ended after their death). Analyses were ﬁt using the R18 function lmerTest::
lmer, and P values and 95% conﬁdence intervals (CIs) were calculated
using the Satterthwaite degrees-of-freedom approximation and Type III
sums of squares (estimating the effect of each predictor over and above
the effect of all others, particularly relevant where predictors are
correlated).
Sulpiride, amisulpride, and mirtazapine are among drugs used for
augmentation of treatment with clozapine,19 and co-prescription was
common. We therefore added drug–drug interaction terms between
clozapine and each of: sulpiride, amisulpride, mirtazapine, aripiprazole, and
olanzapine (thereby including also interactions with other drugs associated
with a reduction in admission days in the 2-year mirror analysis). As the
clozapine × sulpiride and clozapine×mirtazapine interactions were far
from signiﬁcant (P40.5), our ﬁnal regression model included interactions
between clozapine and each of amisulpride, aripiprazole, and olanzapine,
plus all main effects. To exclude the possibility that the effects attributed to
non-clozapine drugs were due to a confound with clozapine treatment or
vice versa, we re-ran the regression for the subset of patients who had
received clozapine at some point, or only those who had not received
clozapine.
RESULTS
Demographics
A total of 1,485 patients had coded diagnoses of schizophrenia
(941 male, 544 female; sex difference, χ21 = 106, P= 6.89 × 10
−25). At
the ﬁrst electronically recorded diagnosis, the median age was
38 years (range 13–93 years, interquartile range 24 years, central
Drug
first
recorded
Before drug (M1) After drug (M2)
Normalized by mean admission
rate across all patients
Normalized by mean admission
rate across all patients
C
entral gap C
2
C
entral gap C
1
Start date (latest of: first coded
diagnosis of schizophrenia, or
January 2005).
Must not follow the start of M1.
End date (earliest of:
December 2012,
or date of death).
Must not precede the end of M2.
Figure 1. Illustration of the mirror-image design. For a given drug, the number of admission days for a given patient was calculated for a
period before the ﬁrst recorded use of the drug (M1, either 1 or 2 years), and a period of identical duration afterwards (M2). These rates were
then corrected for the overall admission rates, for all patients with schizophrenia, during the same M1 and M2 periods (see text). Patients were
excluded who had no admissions falling in the M1 period, thus selecting for patients with relatively severe disease. A central gap (C1+C2, each
30 days) was excluded to reduce the effects of regression to the mean and errors caused by small inaccuracies in the temporal recording
of drugs.
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95% of patients in the range 18.0–77.3), likely reﬂecting a relatively
high proportion of patients with chronic schizophrenia. The data
did not permit the accurate differentiation of new-onset schizo-
phrenia versus chronic schizophrenia recorded electronically for
the ﬁrst time. The median period of follow-up was 4.98 years (from
the ﬁrst to the last letter/admission within the time range,
calculable for 1,310 patients). The sampling method was designed
to be speciﬁc rather than sensitive, and excludes any patients with
schizophrenia whose diagnosis was recorded without ICD-10
coding, or for whom ICD-10 diagnoses were recorded only in free-
text documents. Overall admission rates for schizophrenia
declined substantially over time (from a mean of 49.3 days/year/
patient in 2005 to 10.2 in 2012).
Drug usage and sex differences in prescribing
Table 1 shows drug use rates for antipsychotics and antidepres-
sants. Clozapine, olanzapine, and depot risperidone were all
prescribed proportionally more in males, with no other signiﬁcant
sex differences for antipsychotics. 30.1% of males were prescribed
clozapine at some point, and 21.9% of females (χ2 test,
P= 2.01 × 10−6). For olanzapine, these values were 42.1 and
34.4% (P= 1.31 × 10−9); for depot risperidone, 8.0 and 4.2%
(P= 0.0071). Females were more likely to be prescribed amitripty-
line (5.9% vs. 2.2%, uncorrected P= 4.5 × 10−4), and citalopram
(18.0% vs. 13.6%, P= 0.0274), with no other signiﬁcant sex
differences for antidepressants. Supplementary Table 1 indicates
frequency of consecutive or temporally close co-prescription
between pairs of drugs, and of monotherapy, and shows all drugs
included in the regression analysis.
Precision and recall for clozapine
For clozapine, recall was 1.0. Patient precision was 0.96. Temporal
precision was 0.85.
Mirror analysis: relationship between drug use and admission
Figure 2 shows the mirror-image analyses. Drugs associated
with fewer subsequent admissions in the 1-year analysis were
amisulpride, aripiprazole, clozapine, ﬂuoxetine, mirtazapine,
olanzapine, quetiapine, and sulpiride. Drugs that continued to
be associated with fewer subsequent admissions in the more
stringent 2-year analysis, despite fewer observations, were
aripiprazole, clozapine, olanzapine, and sulpiride. In both analyses,
sulpiride was associated with the largest reduction in subsequent
admissions.
Regression analysis
In the regression analysis (Figure 3), sulpiride and mirtazapine
continued to be associated with a reduction in admissions
(estimated mean change −20.4 and −11.6 days/year, respectively).
The changes were smaller than in the mirror analysis (expected
since all patients were included and statistical control for
other factors was better). Clozapine–aripiprazole and clozapine–
amisulpride combinations were also associated with a signiﬁcant
decrease in admission rates, beyond the effect of either alone
(interaction effects −17.7 and −13.8 days/year, respectively), as
was venlafaxine (−12.3). As noted above, clozapine × sulpiride and
clozapine ×mirtazapine interactions were far from signiﬁcant in
preliminary analysis. Some antipsychotics were associated with an
increase in admission rates, although this method of analysis may
be biased against drug effectiveness (see Discussion). The overall
mean admission rate was 26.8 days/year. Admission rates
decreased with time, but, in addition, time since diagnosis was
negatively associated with admissions.
Within patients who had received clozapine at some point
(n= 402), mirtazapine continued to be negatively associated with
admission days (mean change −22.0 days/year, CI −42.2 to −1.8),
while the effects of sulpiride or venlafaxine, while still negative,
were not credibly different from zero in this subgroup (sulpiride
−18.8, CI −37.7 to +0.2; venlafaxine, −12.4, CI −35.5 to +10.7).
Within the group of patients who had not received clozapine
(n= 1,083), the effect of sulpiride remained strong (mean −19.9, CI
−36.0 to −3.8), while the effects of mirtazapine and venlafaxine
were not credibly different from zero (mirtazapine −4.7, CI −13.5
to +4.1, venlafaxine −8.7, CI −20.6 to +3.3).
Thus, the effect of mirtazapine was statistically independent
of that of clozapine, though numerically stronger in clozapine
users; clozapine and aripiprazole showed signiﬁcant beneﬁcial
synergistic effects, as did clozapine and amisulpride; and
sulpiride showed the largest beneﬁcial effect overall, which was
not solely due to its use as an augmentation strategy for
clozapine.
Table 1. Frequency of drug prescribing
Drug Proportion of
all patients
prescribed drug
at some point
during the study
period (%)
Median daily
dose (for
drugs taken
by ≥ 5% of
patients)
Minimum
effective daily
dose32, where
established
First-generation antipsychotics
Chlorpromazine 12.0 150mg 200mg33 a
Flupentixol 15.7 6mg ?34,35
Fluphenazine 4.0 – –
Haloperidol 20.1 10mg 4mg32
Levomepromazine 0.1 – –
Pericyazine 0.1 – –
Perphenazine 0.1 – –
Pimozide 0.7 – –
Pipotiazine 5.1 7.1 mg 21mg36 a
Prochlorperazine 0.5 – –
Promazine 0.4 – –
Sulpiride 5.7 400mg 400mg33 a
Triﬂuoperazine 7.5 10mg 10mg33 a
Zuclopenthixol 8.8 37.9 mg 14mg37 a
Second-generation antipsychotics
Amisulpride 15.5 400mg 400mg33 a
Aripiprazole 16.8 15mg 10mg32
Asenapine 0.1 – –
Clozapine 27.1 250mgb 300mg32
Olanzapine 39.3 12.5 mg 7.5mg32
Paliperidone 2.4 – –
Quetiapine 17.6 300mg 150mg32
Risperidone 31.9 3.6 mg 2mg32
Antidepressants used by ≥ 5% of patients
Citalopram 15.2 20mg 20mg33
Fluoxetine 10.8 20mg 20mg33
Mirtazapine 10.0 30mg 30mg33
Sertraline 7.3 100mg 50mg33
Venlafaxine 5.9 150mg 75mg33
Second-generation antipsychotics (SGAs) were in general used more than
ﬁrst-generation antipsychotics (FGAs), except for relatively frequent use of
haloperidol (which is often prescribed ‘as required’ in this institution). The
FGA benperidol and the SGAs iloperidone, lurasidone, sertindole,
ziprasidone, and zotepine were not used. The percentages of patients
prescribed a depot medication at some point were: FGAs: haloperidol 2.1%,
ﬂupentixol 12.8%, ﬂuphenazine 3.2%, paliperidone 2.4%, pipotiazine 5.1%,
zuclopenthixol 1.6%; SGAs: olanzapine 0.1%, and risperidone 6.6%.
aEstimate.
bClozapine doses were in some cases electronically underestimated as this
is a drug whose dose is split across the day; for example, ‘clozapine 200 mg
in the morning, 200mg at night’ was misinterpreted as 200mg/day.
Drug treatments and admissions for schizophrenia
RN Cardinal et al
3
© 2015 Schizophrenia International Research Society/Nature Publishing Group npj Schizophrenia (2015) 15035
DISCUSSION
In patients with schizophrenia, we found a signiﬁcant decrease in
admission days after initiation of sulpiride, aripiprazole, clozapine,
and olanzapine, in mirror-image analyses covering 2 years before
and after drug initiation. This analysis focused on patients with
more severe disease, in that they had at least one hospital
admission in the pre-drug period. Sulpiride, mirtazapine, venlafax-
ine, and clozapine–aripiprazole and clozapine–amisulpride com-
binations were associated with a decrease in subsequent time
spent in hospital in a regression analysis across all 1,406 patients,
controlling for the effects of other drugs. All analyses controlled
for overall changes in admission rates unrelated to drug use. Some
drugs in the regression analysis were associated with an increase
in admissions; however, this method may be biased against drug
efﬁcacy (discussed below), so we do not rely on changes in this
direction. In all analyses, the largest beneﬁcial effects were
associated with sulpiride, a drug used relatively infrequently in
local practice.
Methodological considerations
In the mirror-image design, we studied patients who were
relatively unwell by considering only patients who had been
admitted in the pre-drug period. Additional strengths of this
analysis are that it examines a relatively long time period,
represents a within-subjects comparison, and is an intention-
to-treat analysis, since subjects who commenced and then
stopped a given drug are not distinguished from those who
started and continued—in this respect unlike17. A weakness of this
method is the potential for inﬂuence by regression to the mean.
If illness course ﬂuctuates spontaneously and drugs are started
when the illness is severe, natural variation will bias the results in
favour of drug treatments. We attempted to reduce this by the use
of the central exclusion gap but also by using both a temporally
narrow mirror-image analysis (M= 1 year) and a temporally broad
analysis (M= 2 years). Any effect of regression to the mean is less
likely to be observed in the temporally broader analysis. An
additional weakness of the mirror-image design is that it takes no
chlorpromazine (n=41, 43.1y, 31 M)
risperidone (n=82, 41.6y, 56 M)
pipotiazine (n=18, 43y, 12 M)
zuclopenthixol (n=36, 41.9y, 26 M)
citalopram (n=38, 41y, 25 M)
haloperidol (n=64, 44.5y, 41 M)
sertraline (n=20, 39.8y, 9 M)
flupentixol (n=45, 43.3y, 29 M)
venlafaxine (n=19, 39.2y, 11 M)
mirtazapine (n=26, 48.3y, 9 M)
clozapine (n=86, 36.1y, 57 M)
olanzapine (n=86, 41.9y, 59 M)
trifluoperazine (n=23, 46.2y, 15 M)
fluoxetine (n=25, 40.6y, 12 M)
amisulpride (n=41, 42.2y, 22 M)
quetiapine (n=33, 38.3y, 18 M)
aripiprazole (n=48, 40y, 24 M)
sulpiride (n=21, 44.4y, 13 M)
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Change in admission days per year
sertraline (n=14, 38.9y, 7 M)
zuclopenthixol (n=28, 44.1y, 21 M)
chlorpromazine (n=33, 45.6y, 25 M)
citalopram (n=28, 42y, 17 M)
risperidone (n=57, 40.9y, 38 M)
haloperidol (n=52, 43.4y, 36 M)
pipotiazine (n=8, 41y, 4 M)
flupentixol (n=33, 44.9y, 21 M)
amisulpride (n=33, 42.8y, 18 M)
quetiapine (n=27, 40.4y, 15 M)
mirtazapine (n=16, 47.6y, 5 M)
olanzapine (n=67, 41y, 47 M)
trifluoperazine (n=17, 50.2y, 10 M)
clozapine (n=49, 39.4y, 34 M)
fluoxetine (n=19, 41.1y, 11 M)
aripiprazole (n=34, 39.1y, 19 M)
venlafaxine (n=14, 42.7y, 7 M)
sulpiride (n=15, 47.3y, 8 M)
-100 0 100
Change in admission days per year
Figure 2. (a) One-year and (b) 2-year mirror-image analyses, showing the change in admission days per patient per year (admission days per
year after drug, minus admission days per year before drug, corrected for overall admission rates; see Figure 1 and text). The number of
subjects contributing to the measurement for each drug is shown in parentheses (n), with mean age in years (at ﬁrst use of the drug in
question, i.e., in the middle of the period considered) and the number of males (M). Points show means and error bars show 95% CIs; ﬁlled
symbols indicate that the CI excludes zero.
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account of other drugs given at the same time; we addressed this
with a regression analysis.
The regression analysis accounted for the effects of all drugs
considered simultaneously (examining the effects of each drug
over and above all others), accounted for age and estimated
illness duration (over and above calendar time), and examined
drug–drug interactions. A weakness of this method is that a priori
one might expect admissions to be associated with more frequent
documentation in secondary care of a drug history. This would
bias the analysis against effective drugs; therefore, we do not
rely on effects in that direction. However, the analysis highlights
drugs associated with the greatest decrease in admission days.
Another weakness is that admissions may trigger the initiation
of treatment (so causality might ﬂow from admissions to drugs
rather than the reverse).
Comparison to other studies of efﬁcacy and hospitalization in
schizophrenia
Our results are broadly in line with previous evidence of anti-
psychotic efﬁcacy as judged by changes in symptoms or hospitaliza-
tion. A recent meta-analysis20 ranked clozapine, amisulpride, and
olanzapine as the top three for improving symptoms of schizo-
phrenia and for lack of all-cause discontinuation, a combination that
might be expected to reduce hospitalization. Hospitalization beneﬁts
for clozapine and olanzapine have also been observed before.
A double-blind randomized trial favored olanzapine over perphena-
zine, quetiapine, risperidone, or ziprasidone for rehospitalization,2
and a non-blind randomized trial favored clozapine over usual care.3
Non-randomized studies have found hospitalization advantages
for clozapine, versus risperidone or SGAs collectively,4 FGAs,5 depot
FGAs,6 or a pre-clozapine period.7 After a ﬁrst hospitalization for
schizophrenia/schizoaffective disorder, the lowest risk of rehospita-
lization was associated with the use of olanzapine, clozapine, and
perphenazine depot.8 That study did not examine some drugs
associated with fewer admission days in our analysis (sulpiride,
aripiprazole, and mirtazapine) and perphenazine was not used
sufﬁciently in our sample for analysis, but olanzapine and clozapine
were associated with positive beneﬁt in terms of hospitalization in
both studies (at least, in our study, for patients having more frequent
admissions within the mirror-image analysis).
Aripiprazole and amisulpride were associated with beneﬁt when
combined with clozapine. Aripiprazole monotherapy has not
shown better efﬁcacy than other antipsychotics on reducing
readmission;21 however, its use for clozapine augmentation has
shown beneﬁt.9,10 Two small studies have shown some beneﬁts
for amisulpride as clozapine augmentation.22,23 Overall, 27.1% of
patients in our study had been prescribed clozapine at some
point, within the expected range.24,25
(intercept)
quetiapine (n=224)
lorazepam (n=267)
trifluoperazine (n=91)
clozapine:olanzapine (n=147)
citalopram (n=195)
risperidone (n=405)
pipotiazine (n=71)
valproate (n=154)
olanzapine (n=525)
male sex (n=890)
lithium (n=66)
haloperidol (n=257)
amisulpride (n=202)
sertraline (n=91)
aripiprazole (n=210)
diazepam (n=223)
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time since diagnosis
clozapine (n=369)
flupentixol (n=205)
zopiclone (n=318)
chlorpromazine (n=152)
calendar period
fluoxetine (n=137)
clonazepam (n=89)
temazepam (n=64)
zuclopenthixol (n=124)
mirtazapine (n=128)
venlafaxine (n=75)
amisulpride:clozapine (n=96)
aripiprazole:clozapine (n=72)
sulpiride (n=73)
−20 0 20 40 60
Change in admission days per year per patient
Figure 3. Association of admission rates during a given 6-month calendar period with drug use in the preceding calendar period (n= 1,406).
The results are expressed as a change in the number of admission days per patient per year (means± 95% CI); ﬁlled symbols indicate that the
CI excludes zero. Interaction terms are expressed with colon notation. The number of patients taking each drug in at least one time period
(whether alone or with another drug) is shown in parentheses (n); for interactions, this is the number of patients who took both drugs during
the same time period, for at least one period. The effect sizes were derived from a regression analysis taking account of all other antipsychotic
and antidepressant drugs in the analysis (see text), plus 6-month calendar period number (to account for overall trends over time), age, time
since the ﬁrst recorded diagnosis of schizophrenia (in years), and sex.
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Mirtazapine was associated with fewer admission days, in
analyses controlling for other drugs. This was statistically
independent of clozapine. No studies have speciﬁcally examined
the impact of mirtazapine or venlafaxine on admissions in
schizophrenia; however, there is increasing (though heteroge-
neous) evidence that adding mirtazapine can improve negative/
cognitive symptoms.11 Treatment of depression in schizophrenia
might also be an important mode of action, though the effects of
four other conventional antidepressants, ﬂupentixol, or quetiapine
upon admissions were not signiﬁcant or not beneﬁcial.
Perhaps the most striking result in our study was the consistent
and large reduction in admissions associated with sulpiride. The
CUtLASS 1 study26 found that SGAs were not superior to FGAs,
favouring FGAs; of those FGAs, sulpiride was a common choice.
A previous systematic review found little difference between
sulpiride and other antipsychotics.27 However, a recent large
epidemiological study found sulpiride to be associated with less
discontinuation than haloperidol, risperidone, or olanzapine, and
similarly less hospitalization, though the latter difference was not
signiﬁcant.28 There is also some evidence for the use of sulpiride
as clozapine augmentation,29 though in our data the sulpiride
effect did not interact with that of clozapine.
Study strengths
This study has strengths as a naturalistic observational study
across a health care provider, covering a wide range of patient
ages and clinical teams, with natural variation in prescribing
practice. The analytical methods examined the within-subject
effects of all antipsychotics and antidepressants in common use,
controlling statistically for the effects of the other drugs in use and
for temporal factors.
Study weaknesses
Amongst its several weaknesses, the study is observational, not
interventional, so causal conclusions cannot be drawn. For
example, a particular drug associated with better outcomes
may itself be used preferentially by clinical teams that deliver
better care, or be prescribed more for patients whose disease is
more responsive to treatment, or some other such unmeasured
confound. Conversely, a drug may be spuriously associated with
worse outcomes because it is perceived to be clinically effective
and is therefore prescribed for more severely ill patients at the
start of a psychiatric admission.
Some drugs were recorded at median doses below the thera-
peutic minimum (Table 1), speciﬁcally chlorpromazine, pipotiazine,
and clozapine. This represents a source of bias against these
drugs’ effectiveness. In some cases the doses were systematically
underestimated by the NLP-generated drug histories, notably for
split-dose drugs such as clozapine.
In addition, the data are noisy and/or incomplete for several
reasons, leading to a reduction in power and potential bias.
There is likely to have been under recording of schizophrenia
diagnoses, given the generally low rates of ICD-10 diagnostic
coding. In this respect we preferred speciﬁcity over sensitivity, but
it is possible that there was a systematic difference between
patients with schizophrenia who did and did not have their
diagnosis electronically coded. The temporal precision of NLP-
generated drug histories was imperfect. Concomitant treatments
(such as psychotherapy or electroconvulsive therapy) and
concomitant physical illnesses were not measured and represent
an additional source of noise and potential bias. As the drug data
are based on NLP analysis of clinical documents representing
snapshots of each patient when seen in secondary care, use of a
given drug between snapshots was not measured. This weakness
prohibits also accurate characterization of the duration of use of
individual drugs, necessitating an intention-to-treat approach and
likely lowering power (since drugs used only brieﬂy are thus
included), and did not permit an accurate characterization
of illness course. Our data are of signiﬁcantly lower quality than
large data sets including electronic prescription and dispensing
information;30,31 however, they may nonetheless provide novel
suggestions.
The overall decline in admissions is likely to represent primarily
service reorganizations leading to a shift in admission threshold,
thought might also reﬂect a degree of artifact of loss to follow-up
of patients moving to other geographical areas, or improvements
in treatment.
Conclusions
In an observational study of 1,485 patients with schizophrenia in a
secondary mental health care setting, the initiation of sulpiride,
mirtazapine, venlafaxine, or clozapine–aripiprazole and clozapine–
amisulpride combinations was associated with a decrease in
subsequent time spent in hospital, controlling for other drugs. In
simple comparisons of admissions before and after each drug was
started, sulpiride, aripiprazole, clozapine, and olanzapine were
associated with a reduction in subsequent admissions, for patients
admitted in the pre-drug period. The association of clozapine and
olanzapine with a reduction in subsequent admissions has been
observed before, as have some beneﬁts for amisulpride and
aripiprazole as clozapine augmentation, but the association of
sulpiride, mirtazapine, and venlafaxine with these beneﬁts is
novel. Sulpiride was associated with the greatest reduction in
inpatient days in all analyses, independently of clozapine use.
These ﬁndings are not conclusive, do not imply causation, and
should not be used to alter clinical practice but raise hypotheses
requiring conﬁrmation or refutation by randomized controlled
trials.
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